NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00
  • NRX Pharmaceuticals received FDA clearance for an expanded access protocol for NRX-101 to augment accelerated TMS in treatment-resistant depression.
  • The program enables compassionate-use access for patients unable to enroll in the company’s pivotal SPARC-TMS trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220700PRIMZONEFULLFEED9750157) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.